Investors Buy Large Volume of Call Options on Larimar Therapeutics (NASDAQ:LRMR)

Larimar Therapeutics, Inc. (NASDAQ:LRMR) was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 3,744 call options on the stock. This represents an increase of 456% compared to the average volume of 673 call options.

Larimar Therapeutics News Roundup

Here are the key news stories impacting Larimar Therapeutics this week:

• Positive Sentiment: FDA granted Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia, management reiterated a planned BLA submission in June 2026 and target U.S. launch in H1 2027 if approved — a development that materially de-risks the program and supports accelerated approval prospects. Article Title
• Positive Sentiment: Several analysts upgraded or raised price targets (Citigroup to $14 buy, Wedbush reaffirmed outperform with $11 PT, Lifesci Capital to strong-buy), signaling institutional bullishness that can support upside momentum. Article Title
• Neutral Sentiment: Unusual options activity: traders bought ~3,744 calls (≈456% above typical daily call volume), indicating speculative/leveraged bullish positioning that may amplify intraday moves but is not a fundamental change.
• Neutral Sentiment: Media coverage and headlines about the FDA action drove a sharp pre-market surge and massive intraday trading volume (recent reports show daily volume far above the stock’s average), increasing volatility and short-term liquidity. Article Title
• Negative Sentiment: Larimar filed a proposed underwritten public offering of $75 million of common stock (with an underwriter option for an additional $11.25M) — a sizable raise relative to its market cap that introduces near-term dilution risk and can pressure the share price until proceeds are deployed. The offering is subject to market conditions and may create volatility. Article Title

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Leerink Partners raised Larimar Therapeutics to a “strong-buy” rating in a research report on Monday, January 5th. Citigroup lifted their price objective on Larimar Therapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday. Lifesci Capital raised Larimar Therapeutics to a “strong-buy” rating in a research note on Tuesday. Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Larimar Therapeutics in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Larimar Therapeutics has a consensus rating of “Buy” and an average target price of $16.14.

Larimar Therapeutics Stock Performance

Shares of LRMR opened at $5.95 on Thursday. Larimar Therapeutics has a 1 year low of $1.61 and a 1 year high of $6.42. The stock has a market capitalization of $492.54 million, a PE ratio of -3.08 and a beta of 1.00. The stock has a 50-day simple moving average of $3.49 and a 200-day simple moving average of $3.77.

Hedge Funds Weigh In On Larimar Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of LRMR. CWM LLC raised its stake in Larimar Therapeutics by 10.3% in the third quarter. CWM LLC now owns 36,013 shares of the company’s stock valued at $116,000 after buying an additional 3,361 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Larimar Therapeutics by 75.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock worth $33,000 after buying an additional 4,376 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Larimar Therapeutics by 33.9% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 18,248 shares of the company’s stock valued at $59,000 after buying an additional 4,619 shares in the last quarter. Velan Capital Investment Management LP grew its position in shares of Larimar Therapeutics by 17.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 33,000 shares of the company’s stock valued at $95,000 after buying an additional 5,000 shares during the last quarter. Finally, American Century Companies Inc. grew its position in shares of Larimar Therapeutics by 7.8% in the 2nd quarter. American Century Companies Inc. now owns 69,285 shares of the company’s stock valued at $200,000 after buying an additional 5,001 shares during the last quarter. Institutional investors and hedge funds own 91.92% of the company’s stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.